Immunotherapies, for instance, are used in clinical treatment of TNBC [16,17], since this type of breast cancer is very immunogenic [18,19]; additionally, EGFR/HER1, receptors overexpressed in TNBC cells, are being explored for the development of targeted therapies, in fact, phase II clinical trials with EGFR-targeted therapy have shown prolonged progression-free survival and overall survival in metastatic TNBC patients [20]. This evidence concerns the gene EGFR and breast carcinoma.